Clinical trials: Thymic Cancer
Thymic Carcinoma, Non-small Cell Lung Cancer
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint…
- Conditions
- Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
- Trial name
- NCT03583086
- Testing
- Vorolanib, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed…
- Conditions
- Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
- Trial name
- NCT03694002
- Testing
- Carboplatin, Paclitaxel, Ramucirumab
- Where
- 254 sites in United States
- Volunteers
- 21 people
- Sponsor
- SWOG Cancer Research Network
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Thymoma, Thymic Carcinoma
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010257
- Testing
- carboplatin, paclitaxel
- Where
- 67 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Thymoma, Thymus Neoplasms
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Background: Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers. However, it has not been approved to treat cancers of the thymus.
- Trial name
- NCT01621568
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT05583149
- Testing
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Patrick C. Johnson, MD
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03035331
- Testing
- Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Cancer, Solid Tumor
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies.
- Trial name
- NCT03447470
- Testing
- RXC004, Nivolumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 46 people
- Sponsor
- Redx Pharma Ltd
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Thymic Carcinoma
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
- Trial name
- NCT01011439
- Testing
- Milciclib Maleate
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Tiziana Life Sciences LTD
Lung Cancer, Prostate Cancer
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Background: People who have cancer have more medical problems if they smoke. Some studies show that smoking even makes cancer treatment less effective.
- Conditions
- Lung Cancer, Prostate Cancer, Bladder Cancer, Thymic Cancer
- Trial name
- NCT02233842
- Testing
- Participant interview
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Thymus Cancer
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.
- Conditions
- Thymoma, Thymus Cancer, Thymic Carcinoma
- Trial name
- NCT01364727
- Testing
- Amrubicin
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Heather Wakelee